Download PDF
Aktuelle Neurologie 2004; 31(9): 425-434
DOI: 10.1055/s-2003-815008
Neues in der Neurologie
© Georg Thieme Verlag KG Stuttgart · New York

Neues bei Kopfschmerzen 2004

What is New in Headache 2004?H.-C.  Diener1 , V.  Limmroth1 , A.  May2
  • 1Klinik für Neurologie, Universitätsklinik Essen
  • 2Klinik für Neurologie, Universität Regensburg und Hamburg
Mit Unterstützung des Bundesministeriums für Bildung und Forschung (BMBF) im Rahmen des Kompetenznetzes Kopfschmerz (01EM0117).Diese Übersicht erscheint in leicht modifizierter Version in den Zeitschriften Aktuelle Neurologie und Arzneimitteltherapie
Further Information

Publication History

Publication Date:
28 October 2004 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Neue wissenschaftliche Daten und Erkenntnisse zur Pathophysiologie und Genetik von Kopfschmerzerkrankungen haben zur Etablierung neuer Tiermodelle und zur Entwicklung neuer Substanzen zur Therapie und Prophylaxe beigetragen. Diese Übersicht fasst neue Erkenntnisse und Studien zu Kopfschmerzen und ihre Therapie zusammen.

Abstract

Recently new scientific data were gained regarding genetics and pathophysiology of headache disorders. Animal models were established and improved the development of new drugs for acute therapy and prophylaxis. This review summarises studies on headache published in 2003 and 2004.

Literatur

  • 1 Headache Classification Committee of the International Headache Society . Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.  Cephalalgia. 1988;  8, Suppl 7 1-93
    CrossrefPubMedGoogle Scholar
  • 2 Olesen J, Bousser M-G, Diener H. et al . The International Classification of Headache Disorders. 2nd Edition.  Cephalalgia. 2004;  24, Suppl 1 1-160
    PubMedGoogle Scholar
  • 3 Rasmussen B K. Epidemiology. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The Headaches. New York; Raven Press 1993: 439-443
    Google Scholar
  • 4 Ulrich V, Gervil M, Kyvik K O. et al . Evidence of a genetic factor in migraine with aura: a population-based danish twin study.  Ann Neurol. 1999;  45 242-246
    CrossrefPubMedGoogle Scholar
  • 5 Joutel A, Bousser M, Biousese V. et al . A gene for familial hemiplegic migraine maps to chromosome 19.  Nature Genetics. 1993;  5 40-45
    CrossrefPubMedGoogle Scholar
  • 6 Ophoff R A, Terwindt G M, Vergouwe M N. et al . Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNLA4.  Cell. 1996;  87 543-552
    CrossrefPubMedGoogle Scholar
  • 7 Fusco M De, Marconi R, Silvestri L. et al . Haploinsufficiency of ATP1A2 encoding the Na/K pump alpha2 subunit associated with familial hemiplegic migraine type 2.  Nature Genetics. 2003;  33 192-196
    CrossrefPubMedGoogle Scholar
  • 8 Ophoff R A, Terwindt G M, Frants R R. et al . P/Q-type Ca2+ channel defects in migraine, ataxia and epilepsy.  TiPS. 1998;  19 121-127
    PubMedGoogle Scholar
  • 9 Moskowitz M, Bolay H, Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes.  Ann Neurol. 2004;  55 276-280
    CrossrefPubMedGoogle Scholar
  • 10 Vanmolkot K, Kors E, Hottenga J. et al . Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions.  Ann Neurol. 2003;  54 360-366
    CrossrefPubMedGoogle Scholar
  • 11 Thomsen L L, Ostergaard E, Olesen J. et al . Evidence for a separate type of migraine with aura: Sporadic hemiplegic migraine.  Neurology. 2003;  25 595-601
    PubMedGoogle Scholar
  • 12 Terwindt G, Kors E, Haan J. et al . Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine.  Arch Neurol. 2002;  59 1016-1018
    CrossrefPubMedGoogle Scholar
  • 13 Terwindt G M, Ophoff R A, Haan J. et al . Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine.  Neurology. 1998;  50 1105-1110
    PubMedGoogle Scholar
  • 14 Chapman K, Szczygielski B, Toth C. et al . Pseudomigraine with lymphocytic pleocytosis: a calcium channelopathy? Clinical description of 10 cases and genetic analysis of the familial hemiplegic migraine gene CACNA1A.  Headache. 2003;  43 892-895
    CrossrefPubMedGoogle Scholar
  • 15 Wang S, Fuh J, Lu S. et al . Migraine prevalence during menopausal transition.  Headache. 2003;  43 470-478
    CrossrefPubMedGoogle Scholar
  • 16 Winner P, Wasiewski W, Gladstein J. et al . Multicenter prospective evaluation of proposed pediatric migraine revisions to the IHS criteria.  Headache. 1997;  37 545-548
    CrossrefPubMedGoogle Scholar
  • 17 Winner P, Rothner A, Putnam D. et al . Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials' database.  Headache. 2003;  43 451-457
    CrossrefPubMedGoogle Scholar
  • 18 Evans R, Lipton R, Silberstein S. The prevalence of migraine in neurologists.  Neurology. 2003;  61 1271-1272
    PubMedGoogle Scholar
  • 19 Kruit M, Buchem M van, Hofman P. et al . Migraine as a risk factor for subclinical brain lesions.  JAMA. 2004;  291 427-434
    CrossrefPubMedGoogle Scholar
  • 20 Harno H, Hirvonen T, Kaunisto M. et al . Subclinical vestibulocerebellar dysfunction in migraine with and without aura.  Neurology. 2003;  61 1748-1752
    CrossrefPubMedGoogle Scholar
  • 21 Chang C L, Donaghy M, Poulter N. et al . Migraine and stroke in young women: case-control study.  BMJ. 1999;  318 13-18
    CrossrefPubMedGoogle Scholar
  • 22 Welch K MA, Bousser M-G. Migraine and stroke. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The Headaches. 2nd ed. Philadelphia; Lippincott Williams & Wilkins 2000: 529-542
    Google Scholar
  • 23 Diener H, Welch K, Mohr J P. Migraine and stroke. In: Mohr J, Choi D, Grotta J, Wolf P (eds) Stroke. Pathophysiology, diagnosis and management. Philadelphia; Churchill Livingstone 2004
    Google Scholar
  • 24 Donaghy M, Chang C L, Poulter N. et al . Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age.  J Neurol Neurosurg Psychiatry. 2002;  73 747-750
    CrossrefPubMedGoogle Scholar
  • 25 Breslau N, Davis G C. Migraine, major depression and panic disorder: a prospective epidemiologic study of young adults.  Cephalalgia. 1992;  12 85-90
    CrossrefPubMedGoogle Scholar
  • 26 Breslau N, Schultz L R, Stewart W F. et al . Headache and major depression. Is the association specific to migraine?.  Neurology. 2000;  54 308-313
    CrossrefPubMedGoogle Scholar
  • 27 Bahra A, Goadsby P J. The comorbidity of migraine and depression: a review.  Neurology and Psychiatry. 1998;  2 23-27
    PubMedGoogle Scholar
  • 28 Breslau N LR, Stewart W F, Schultz L R, Welch K M. Comorbidity of migraine and depression: Investigating potential etiology and prognosis.  Neurology. 2003;  60 1308-1312
    CrossrefPubMedGoogle Scholar
  • 29 Lipton R B, Silberstein S D. Neurologic and psychiatric comorbidity with migraine.  Neurology. 1994;  44 S1-S47
    PubMedGoogle Scholar
  • 30 Leniger T, Diener H-C. Migräne und Komorbidität. In: Diener H-C (Hrsg) Kopfschmerzen. Stuttgart; Thieme 2003: 58-60
    Google Scholar
  • 31 Sztajzel R, Genoud D, Roth S. et al . Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke.  Cerebrovasc Dis. 2002;  13 102-106
    PubMedGoogle Scholar
  • 32 Carerj S, Narbone M, Zito C. et al . Prevalence of atrial septal aneurysm in patients with migraine: an echocardiographic study.  Headache. 2003;  43 725-728
    CrossrefPubMedGoogle Scholar
  • 33 Diener H-C, Hartung E, Chrubasik J. et al . A comparative study of acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomised, controlled, double-blind, parallel group phase III study.  Cephalalgia. 2001;  21 140-144
    CrossrefPubMedGoogle Scholar
  • 34 Leniger T, Driesch S von den, Isbruch K. et al . Clinical characteristics of patients with comorbidity of migraine and epilepsy.  Headache. 2003;  43 672-677
    CrossrefPubMedGoogle Scholar
  • 35 Leniger T D, Diener H C, Hufnagel A. Erhöhte zerebrale Erregbarkeit und „spreading depression” Ursachen für eine Komorbidität von Epilepsie und Migräne?.  Nervenarzt. 2003;  74 869-874
    CrossrefPubMedGoogle Scholar
  • 36 The Diclofenac-K/Sumatriptan Migraine Study Group . Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo.  Cephalalgia. 1999;  19 232-240
    CrossrefPubMedGoogle Scholar
  • 37 Thomas H M, Kudrow D B, Ashford E. et al . A phase III multicentre, randomised, double-blind, parallel-group study of valdecoxib 40 mg vs placebo in patients with multiple moderate or severe acute migraine headaches with and without aura (abstract).  Cephalalgia. 2003;  23 697
    PubMedGoogle Scholar
  • 38 Diener H-C, Reches A, Pascual J. et al . Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.  Europ Neurol. 2002;  47 99-107
    CrossrefPubMedGoogle Scholar
  • 39 The Multinational Oral Sumatriptan Cafergot Comparative Study Group . A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine.  Eur Neurol. 1991;  31 314-322
    PubMedGoogle Scholar
  • 40 Charlesworth B, Dowson A, Purdy A. et al . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.  CNS Drugs. 2003;  17 653-667
    PubMedGoogle Scholar
  • 41 Göbel H, Boswell D, Winter P DO. et al .A comparison of the efficacy and tolerability of naratriptan and sumatriptan among migraineurs with a history of frequent (50 % of attacks) headache recurrence. Amsterdam; Poster, VIIIth IHS Congress 1997: 163-165
    Google Scholar
  • 42 Sheftell F, O'Quinn S, Watson C. et al . Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence.  Headache. 2000;  40 103-110
    CrossrefPubMedGoogle Scholar
  • 43 Tfelt-Hansen P, Teall J, Rodriguez F. et al . Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine.  Headache. 1998;  38 748-755
    CrossrefPubMedGoogle Scholar
  • 44 Goldstein J, Ryan R, Jiang K. et al . Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine.  Headache. 1998;  38 737-747
    CrossrefPubMedGoogle Scholar
  • 45 Tfelt-Hansen P, Ryan R E. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials.  Neurology. 2000;  55, Suppl 2 S19-S24
    PubMedGoogle Scholar
  • 46 Goadsby P J, Ferrari M D, Olesen J. et al . Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan.  Neurology. 2000;  54 156-163
    CrossrefPubMedGoogle Scholar
  • 47 Sandrini G, Färkkilä M, Burgess G. et al . Eletriptan vs sumatriptan. A double-blind, placebo-controlled, multiple migraine attack study.  Neurology. 2002;  59 1210-1217
    CrossrefPubMedGoogle Scholar
  • 48 Diener H, Ryan R, Sun W. et al . The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg.  Eur J Neurol. 2004;  11 125-134
    CrossrefPubMedGoogle Scholar
  • 49 Garcia-Ramos G, MacGregor E, Hilliard B. et al . Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.  Cephalalgia. 2003;  23 869-876
    CrossrefPubMedGoogle Scholar
  • 50 Steiner T, Diener H, MacGregor E. et al . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine.  Cephalalgia. 2003;  23 942-952
    CrossrefPubMedGoogle Scholar
  • 51 Pascual J, Falk R, Docekal R. et al . Tolerability and efficacy of almotriptan in the long-term treatment of migraine.  Eur Neurol. 2001;  45 206-213
    CrossrefPubMedGoogle Scholar
  • 52 Dowson A J, Massiou H, Lainez J M. et al . Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomised, double-blind, placebo-controlled clinical trial.  Cephalalgia. 2002;  22 453-461
    CrossrefPubMedGoogle Scholar
  • 53 Visser W H, Vriend R HM de, Jaspers N. et al . Sumatriptan - nonresponders: a survey in 366 migraine patients.  Headache. 1996;  36 471-475
    CrossrefPubMedGoogle Scholar
  • 54 Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia.  Ann Neurol. 2004;  55 19-26
    CrossrefPubMedGoogle Scholar
  • 55 Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.  Ann Neurol. 2004;  55 27-36
    CrossrefPubMedGoogle Scholar
  • 56 Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine.  Headache. 2003;  43 1075-1079
    CrossrefPubMedGoogle Scholar
  • 57 Mathew N, Schoenen J, Winner P. et al . Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.  Headache. 2003;  43 214-222
    CrossrefPubMedGoogle Scholar
  • 58 Färkkilä M, Olesen J, Dahlof C. et al . Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan.  Cephalalgia. 2003;  23 463-471
    CrossrefPubMedGoogle Scholar
  • 59 Chia Y, Lim S, Wang S. et al . Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs.  Headache. 2003;  43 984-990
    CrossrefPubMedGoogle Scholar
  • 60 Mathew N, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.  Headache. 2003;  43 962-974
    CrossrefPubMedGoogle Scholar
  • 61 Christie S, Göbel H, Mateos V. et al . Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.  Eur Neurol. 2002;  49 20-29
    PubMedGoogle Scholar
  • 62 Baos V, Serrano A, Torrecilla M. et al . Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting.  Int J Clin Pract. 2003;  57 761-768
    PubMedGoogle Scholar
  • 63 Schulman E, Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs.  Headache. 2003;  43 729-733
    CrossrefPubMedGoogle Scholar
  • 64 The Subcutaneous Sumatriptan International Study Group . Treatment of migraine attacks with sumatriptan.  N Engl J Med. 1991;  325 316-321
    PubMedGoogle Scholar
  • 65 Diener H-C. for the ASASUMAMIG Study Group . Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study.  Cephalalgia. 1999;  19 581-588
    CrossrefPubMedGoogle Scholar
  • 66 Stillman M, Zajac D, Rybicki L. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience.  Headache. 2004;  44 65-69
    CrossrefPubMedGoogle Scholar
  • 67 Goadsby P J, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.  Ann Neurol. 1990;  28 183-187
    CrossrefPubMedGoogle Scholar
  • 68 Doods H, Hallermayer G, Wu D. et al . Pharmacological profil of BIBN4096BS, the first selective small molecule CGRP antagonist.  Br J Pharmacol. 2000;  129 420-423
    CrossrefPubMedGoogle Scholar
  • 69 Olesen J, Diener H, Husstedt I W. et al . Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks.  N Engl J Med. 2004;  350 1104-1110
    CrossrefPubMedGoogle Scholar
  • 70 Eikermann A D, Diener H C. Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine.  Cephalalgia. 2003;  23 344-347
    CrossrefPubMedGoogle Scholar
  • 71 Reuter U, Sanchez Del Rio M, Carpay J. et al . Placebo adverse events in headache trials: headache as an adverse event of placebo.  Cephalalgia. 2003;  23 496-503
    CrossrefPubMedGoogle Scholar
  • 72 Diener H-C. und die Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (Hrsg) .Leitlinien für Diagnostik und Therapie in der Neurologie. 2. ed. Stuttgart; Thieme 2003
    Google Scholar
  • 73 Brandes J, Saper J, Diamond M. et al . Topiramate for migraine prevention: a randomized controlled trial.  JAMA. 2004;  291 965-973
    CrossrefPubMedGoogle Scholar
  • 74 Martinez H, Londono O, Cantu-Martinez L. et al . Topiramate as an adjunctive treatment in migraine prophylaxis.  Headache. 2003;  43 1080-1084
    CrossrefPubMedGoogle Scholar
  • 75 Silvestrini M, Bartolini M, Coccia M. et al . Topiramate in the treatment of chronic migraine.  Cephalalgia. 2003;  23 820-824
    CrossrefPubMedGoogle Scholar
  • 76 Tronvik E, Stovner L, Helde G. et al . Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.  JAMA. 2003;  289 65-69
    CrossrefPubMedGoogle Scholar
  • 77 Gallai V, Alberti A, Rossi C. et al . An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine.  J Headache Pain. 2003;  4 92-96
    CrossrefPubMedGoogle Scholar
  • 78 Koseoglu E, Akboyraz A, Soyuer A. et al . Aerobic exercise and plasma beta endorphin levels in patients with migrainous headache without aura.  Cephalalgia. 2003;  23 972-976
    CrossrefPubMedGoogle Scholar
  • 79 Matharu M, Bartsch T, Ward N. et al . Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study.  Brain. 2003;  127 220-230
    PubMedGoogle Scholar
  • 80 Zagami A S. Chronic tension-type headache - rational drug treatment options.  CNS Drugs. 1995;  4 90-98
    PubMedGoogle Scholar
  • 81 Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: A placebo controlled double-blind cross-over study.  Headache. 1992;  32 509-513
    CrossrefPubMedGoogle Scholar
  • 82 Murros K, Kataja M, Hedman C. et al . Modified-release formulation of tizanidine in chronic tension-type headache.  Headache. 2000;  40 633-637
    CrossrefPubMedGoogle Scholar
  • 83 Shimomura T, Awaki E, Kowa H. et al . Treatment of tension-type headache with tizanidine hydrochloride: Its efficacy and relationship to the plasma MHPG concentration.  Headache. 1991;  31 601-604
    CrossrefPubMedGoogle Scholar
  • 84 Holroyd K, Labus J, O'Donnell F. et al . Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation.  Headache. 2003;  43 999-1004
    CrossrefPubMedGoogle Scholar
  • 85 Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but no a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache.  J Neurol Neurosurg Psychiatry. 1996;  61 285-290
    CrossrefPubMedGoogle Scholar
  • 86 Torelli P, Jensen R, Olesen J. Physiotherapy for tension-type headache: a controlled study.  Cephalalgia. 2004;  24 29-36
    CrossrefPubMedGoogle Scholar
  • 87 Bahra A, May A, Goadsby P J. Cluster headache: a prospective clinical study with diagnostic implications.  Neurology. 2002;  58 354-361
    CrossrefPubMedGoogle Scholar
  • 88 Ekbom K, Monstad I, Prusinski A. et al . Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study.  Acta neurol Scand. 1993;  88 63-69
    PubMedGoogle Scholar
  • 89 Limmroth V, May A, Diener H-C. Der Stellenwert von Sumatriptan in der Anfallstherapie der Migräne und des Clusterkopfschmerzes.  Nervenheilkunde. 1996;  15 100-108
    PubMedGoogle Scholar
  • 90 Vliet J A Van, Bahra A, Martin V. et al . Intranasal sumatriptan in cluster headache: Randomized placebo-controlled double-blind study.  Neurology. 2003;  60 630-633
    PubMedGoogle Scholar
  • 91 Lainez M, Pascual J, Pascual A. et al . Topiramate in the prophylactic treatment of cluster headache.  Headache. 2003;  43 784-789
    CrossrefPubMedGoogle Scholar
  • 92 Leone M, Dodick D, Rigamonti A. et al . Topiramate in cluster headache prophylaxis: an open trial.  Cephalalgia. 2003;  23 1001-1002
    CrossrefPubMedGoogle Scholar
  • 93 Mulder L J, Spierings E L. Naratriptan in the preventive treatment of cluster headache.  Cephalalgia. 2002;  22 815-817
    CrossrefPubMedGoogle Scholar
  • 94 May A, Goadsby P J. Neuroimaging of cluster headache. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The Headaches. 2nd ed. Philadelphia; Lippincott Williams & Wilkins 2000: 703-708
    Google Scholar
  • 95 May A, Bahra A, Büchel C. et al . PET and MRA findings in cluster headache and MRA in experimental pain.  Neurology. 2000;  55 1328-1335
    PubMedGoogle Scholar
  • 96 May A, Bahra A, Buchel C. et al . Hypothalamic activation in cluster headache attacks.  Lancet. 1998;  352 275-278
    CrossrefPubMedGoogle Scholar
  • 97 Sprenger T, Bocker H, Tolle T R. et al . Specific hypothalamic activation during a spontaneuos cluster headache attack.  Neurology. 2004;  62 516-517
    PubMedGoogle Scholar
  • 98 Franzini A, Ferroli P, Leone M. et al . Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series.  Neurosurgery. 2003;  52 1095-1101
    CrossrefPubMedGoogle Scholar
  • 99 Leone M, Franzini A, D'Amico D. et al . Stereotactic electrode implant in inferior posterior hypothalamic gray matter to relieve intractable chronic cluster headache: the first reported case.  Neurology. 2001;  56, Suppl 3 A218
    PubMedGoogle Scholar
  • 100 Leone M, Franzini A, Broggi G. et al . Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow up.  J Neurol Sci. 2003;  24, Suppl 2 143-145
    PubMedGoogle Scholar
  • 101 Dichgans J, Diener H-C, Gerber W D. et al . Analgetika-induzierter Dauerkopfschmerz.  Dtsch med Wschr. 1984;  109 369-373
    PubMedGoogle Scholar
  • 102 Katsarava Z, Fritsche G, Muessig M. et al . Clinical features of withdrawal headache following overuse of triptans and other headache drugs.  Neurology. 2001;  57 1694-1698
    PubMedGoogle Scholar
  • 103 Limmroth V, Katsarava Z, Fritsche G. et al . Features of medication overuse headache following overuse of different acute headache drugs.  Neurology. 2002;  59 1011-1014
    CrossrefPubMedGoogle Scholar
  • 104 Rozen T. Melatonin as treatment for idiopathic stabbing headache.  Neurology. 2003;  61 865-866
    PubMedGoogle Scholar
  • 105 Dodick D W, Mosek A C, Campbell J K. The hypnic („alarm clock”) headache syndrome.  Cephalalgia. 1998;  18 152-156
    CrossrefPubMedGoogle Scholar
  • 106 Raskin N H. The hypnic headache syndrome.  Headache. 1988;  28 534-536
    CrossrefPubMedGoogle Scholar
  • 107 Sibon I, Ghorayeb I, Henry P. Successful treatment of hypnic headache syndrome with acetazolamide.  Neurology. 2003;  61 1157-1158
    PubMedGoogle Scholar
  • 108 Higgins J, Cousins C, Owler B. et al . Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting.  J Neurol Neurosurg Psychiatry. 2003;  74 1662-1666
    CrossrefPubMedGoogle Scholar

Prof. Dr. Hans-Christoph Diener

Universitätsklinik für Neurologie · Universitätsklinikum Essen

Hufelandstraße 55

45122 Essen

Email: h.diener@uni-essen.de